0.1350CADMkt Cap: 16.98M CADP/E: —Last update: 2026-05-21
Avicanna Inc., a commercial-stage biopharmaceutical company, engages in the research, development, advancement, and commercialization of evidence-based cannabinoid-based products and formulations for medical and pharmace…
Industry Peers
Drug Manufacturers - Specialty & Generic153.14BSEKP/E 168.3
54.96BEURP/E 21.7
52.53BTRYP/E 27.3
33.63BPLNP/E 21.9
13.36BSEKP/E 40.3
13.24BEURP/E 30.2
12.58BTRY—
3.96BUSDP/E 33.6
loading…
Indicators:|
Key Statistics
Company
Market Cap16.98M CAD
Enterprise Value24.62M CAD
Revenue (TTM)25.83M CAD
Gross Profit13.52M CAD
Net Income (TTM)-2.84M CAD
Revenue/Share0.2210 CAD
Last Price0.1350 CAD
Fiscal Year EndDec 2025
MR QuarterMar 2026
Employees112
CountryCA
SectorHealthcare
IndustryDrug Manufacturers - Specialty & Generic
ISINCA05368K1003
Valuation
P/E (Trailing)—
P/E (Forward)-2.25
PEG—
EV/EBITDA-9.21
EV/Revenue0.95
P/S0.66
P/B4.09
EPS (TTM)-0.02
EPS (Forward)-0.06
52W Range
0.130025% of range0.1500
52W High0.1500 CAD
52W Low0.1300 CAD
Profitability
Gross Margin53.06%
Oper. Margin-4.63%
EBITDA Margin-10.35%
Profit Margin-11.16%
ROE-100.02%
ROA-13.39%
Growth
Revenue Growth5.60%
Earnings Growth—
Cash Flow & Leverage
Operating CF-1.18M CAD
CapEx (TTM)255.87K CAD
FCF Margin-5.38%
FCF Yield-8.18%
Net Debt-372.10K CAD
Net Debt/EBITDA0.14
Balance Sheet
Debt/Equity0.00
Current Ratio0.96
Quick Ratio0.44
Book Value/Sh0.0330 CAD
Cash/Share0.0030 CAD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 CAD
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating—
Target (Mean)—
Target Range—
# Analysts—
Ownership
Shares Out.125.79M
Float104.29M
Insiders22.97%
Institutions0.00%
Short Interest
Short Ratio0.3d
Short % Out.0.03%
Shares Short41.32K
Short (prev mo.)25.79K
Technical
SMA 500.1501 (-10.1%)
SMA 2000.2156 (-37.4%)
Beta—
S&P 52W Chg28.31%
Avg Vol (30d)429.80K
Avg Vol (10d)186.05K
Technical Indicators
RSI (14)—
MACD—
MACD Signal—
MACD Hist.—
BB Upper—
BB Middle—
BB Lower—
BB Width—
ATR (14)—
Vol Ratio (20d)—